The global small-scale bioreactors industry is predicted to register a CAGR of 14.8% over the forecast period, as per FMI’s analysis. The industry’s size is anticipated to increase from USD 1.94 billion in 2023 to USD 7.71 billion by 2033 end.
New therapies are expected to be increasingly developed in the coming years due to the increased likelihood demand for dedicated manufacturing processes. These processes can be successfully achieved by the use of small-scale bioreactors, consequently leading to their high demand.
As the years go by, automation and control systems are constantly improving alongside. As a result, it is expected to become easier to optimize and regulate small-scale bioreactors, making them more cost-friendly and efficient.
Moreover, heightened adoption of ceaseless manufacturing processes has been witnessed. Thus, gaining popularity in the pharmaceutical industry is aptly suited for the use of small-scale bioreactors. The booming pharmaceutical industry is expected to be favorable for these bioreactors in the years to come.
Advances in gene and cell therapies and their consequent approval by relevant authorities are expected to enhance the market scope for small-scale bioreactors. This can be ascribed to the increasing demand for scalable and versatile manufacturing processes. Thus leading to successful recognition by the use of small-scale bioreactors.
Immunization campaigns throughout the world over are expected to enhance product sales in the stipulated time frame. Moreover, government bodies across the world are financially supporting biopharmaceutical research. For instance, in April 2020, the government of South Korea allocated USD 250 million to introduce the Vaccine Innovative Technology Alliance (VITAL). This is expected to help with vaccine production, research, and use.
Going forward, the demand for personalized medicine is anticipated to grow. As a result, the demand for small-scale bioreactors to develop small batches of customized therapies is expected to bolster market growth. In addition to this, the market is also observing an upsurge in the trend of patient-centric healthcare.
Top Highlights from the FMI’s Analysis of the Small-scale Bioreactors industry:
- The 1L–3L capacity segment led the market, by acquiring more than 31% of the total market revenue in 2022.
- The reusable bioreactors segment held more than 80.05% in 2022 and is predicted to maintain its dominance in the years to come.
- The single-use bioreactors segment is anticipated to expand at a robust pace over the forecast period.
- The North America market is expected to lead the market over the stipulated time frame.
- The Asia Pacific market is projected to expand at a robust pace in the assessment period.
Growing Need for Market Insights: Access Our Full Report for Thorough Analysis and Trends!
Key Updates from the Small-scale Bioreactors industry Regarding its Competitive Side:
- In December 2022, Inceptor Bio and Ori Biotech came together to support the nascent level process development. To upscale the growth of Inceptor’s distinct CAR-M, CAR-NK, and CAR-T programs. Inceptor Bio is a third partner to sign up for LightSpeed Early Access Program (LEAP) by Ori. The company can now deploy the fully automated CGT manufacturing platform and digital capabilities before its commercial availability.
- In April 2022, Lonza and Luzhu Biotech entered a commercial and research license agreement. The agreement aims to utilize GS piggyBac transposon technology and Gene Expression System by Lonza.
Enlisted below are the key players in the market
- Sartorius AG
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Lonza Group
- Eppendorf AG
- Miltenyi Biotec
- Getinge AB
- Solaris Biotechnology Srl
- Infors AG
Small-scale Bioreactors industry by Category
By Product, the Small-scale Bioreactors Industry is segmented as:
- Small-scale Reusable Bioreactors
- Small-scale Stainless Steel Bioreactors
- Small-scale Glass Bioreactors
- Small-scale Single-use Bioreactors
By Capacity, the Small-scale Bioreactors Industry is categorized as:
- Small-scale Bioreactors of 5 ML -100 ML Capacity
- Small-scale Bioreactors of 100 ML-250 ML Capacity
- Small-scale Bioreactors of 250 ML -500 ML Capacity
- Small-scale Bioreactors of 500 ML-1 L Capacity
- Small-scale Bioreactors of 1L-3L Capacity
- Small-scale Bioreactors of 3L-5L Capacity
By End User, the Small-scale bioreactors industry is segregated as:
- Small-scale Bioreactors for Pharmaceutical & Biopharmaceutical Companies
- Small-scale Bioreactors for CROs & CMOs
- Small-scale Bioreactors for Academic & Research Institutes
By Region, the Industry of Small-scale Bioreactors is segmented as:
- Small-scale Bioreactors in North America Market
- Small-scale Bioreactors in Europe Market
- Small-scale Bioreactors in Asia Pacific Market
- Small-scale Bioreactors in Latin America Market
- Small-scale Bioreactors in the Middle East and Africa Market
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
